The company clarified that the effectiveness of the drug depends on the age of the patients and the strain of the coronavirus.
According to TASS, a press release from the company, published on its website on Wednesday, said that the effectiveness of the coronavirus vaccine, developed by the Tübingen-based pharmaceutical company CureVac, is only 47% effective in the main phase of clinical trials.
“CureVac today announced the results of the second interim analysis of an international mainstream 2b / 3 study of the first generation CVnCoV COVID-19 candidate vaccine, in which approximately 40,000 people participated”, – the report said.
At the same time, it is indicated that the study examined 134 cases of coronavirus infection that occurred at least two weeks after the second dose of the drug was administered. Of these, 124 cases were included in this analysis.
“The CVnCoV candidate vaccine has shown an intermediate 47% efficacy against COVID-19 disease of any severity and did not meet predetermined statistical success criteria”, – the statement said.